Dosage and Administration Guidelines for Erlotinib

Erlotinib is a targeted therapeutic agent directed against specific gene mutations, primarily indicated for the treatment of non-small cell lung cancer and advanced pancreatic cancer. Its use must be under the guidance of a qualified physician, with dosing regimens strictly individualized based on each patient’s condition.

Patient Selection for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Selection of patients with metastatic NSCLC for treatment with Erlotinib (TARCEVA) is based on the presence of either an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation in tumor or plasma specimens.

Recommended Dosage

I. Usual Adult Dose for Non-Small Cell Lung Cancer

Dosage and Administration

Orally, once daily, 150 mg per dose, administered on an empty stomach (at least 1 hour before or 2 hours after a meal).

Duration of Treatment

Continue until disease progression or unacceptable toxicity occurs.

Indications

For patients with metastatic NSCLC whose tumors harbor EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. Specific clinical settings include:

First-line treatment,Maintenance treatment

Second- or subsequent-line treatment in patients with disease progression following at least one prior chemotherapy regimen

II. Usual Adult Dose for Pancreatic Cancer

Dosage and Administration

Orally, once daily, 100 mg per dose, administered on an empty stomach (at least 1 hour before or 2 hours after a meal).

Duration of Treatment

Continue until disease progression or unacceptable toxicity occurs.

Indications

In combination with gemcitabine, for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer.

Dosage Adjustment

If treatment is interrupted due to dose-limiting toxicity, upon recovery of toxicity to baseline or Grade ≤1, erlotinib dosage should be reduced by 50 mg per decrement. For details, refer to Drug Interactions.

I. Dosage Adjustment for Adverse Reactions

1. Pulmonary Adverse Reactions

Interstitial Lung Disease (ILD): Interrupt erlotinib during diagnostic evaluation for suspected ILD. Discontinue erlotinib if ILD is confirmed.

2. Hepatic Adverse Reactions

Discontinue erlotinib in patients with severe hepatic toxicity that does not improve significantly or resolve completely within 3 weeks.

For patients with pre-existing hepatic impairment or biliary obstruction: interrupt erlotinib and consider discontinuation if bilirubin doubles from baseline or transaminases increase to 3 times baseline.

For patients without pre-existing hepatic impairment: interrupt erlotinib and consider discontinuation if total bilirubin exceeds 3 times the upper limit of normal (ULN) or transaminases exceed 5 times ULN.

3. Renal Adverse Reactions

Interrupt erlotinib and consider discontinuation in the event of severe (CTCAE Grade 3–4) renal toxicity.

4. Gastrointestinal Adverse Reactions

Discontinue erlotinib if gastrointestinal perforation occurs.

Interrupt erlotinib in cases of persistent severe diarrhea unresponsive to pharmacologic therapy (e.g., loperamide).

5. Skin Adverse Reactions

Discontinue erlotinib if severe bullous, blistering, or exfoliative skin conditions develop.

Interrupt erlotinib for severe rash unresponsive to pharmacologic treatment.

6. Ocular Adverse Reactions

Discontinue erlotinib in the event of corneal perforation or severe corneal ulceration.

Interrupt erlotinib for NCI-CTC (Version 4.0) Grade 3–4 keratitis, or Grade 2 keratitis lasting more than 2 weeks.

Interrupt erlotinib and consider discontinuation for acute/worsening ocular disorders (e.g., eye pain).

II. Dosage Adjustment for Drug Interactions

1. Cytochrome P450 3A4 (CYP3A4) Inhibitors

If erlotinib is co-administered with strong CYP3A4 inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), voriconazole, or grapefruit/grapefruit juice), or with agents that inhibit both CYP3A4 and CYP1A2 (e.g., ciprofloxacin) and severe reactions occur, reduce erlotinib dosage by 50 mg per decrement. Concomitant use should be avoided if possible.

2. Cytochrome P450 3A4 (CYP3A4) Inducers

If erlotinib is co-administered with CYP3A4 inducers (e.g., rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, or St. John’s Wort), increase erlotinib dosage by 50 mg every 2 weeks, up to a maximum of 450 mg daily (as tolerated by the patient). Concomitant use should be avoided if possible.

III. Dosage Adjustment in Current Smokers

In patients who currently smoke, increase erlotinib dosage by 50 mg every 2 weeks, up to a maximum of 300 mg daily. Immediately reduce erlotinib to the recommended dose (150 mg or 100 mg daily) once smoking is discontinued.

IV. Dosage Adjustment with Concomitant Acid-Reducing Agents

1. Proton Pump Inhibitors (PPIs)

PPIs cause prolonged elevation of upper gastrointestinal pH, and drug interactions may not be avoided even with staggered dosing. Concomitant use with erlotinib should be avoided if possible.

2. H2-Receptor Antagonists

If an H2-receptor antagonist (e.g., ranitidine) is required, stagger administration: erlotinib should be taken 10 hours after the H2-receptor antagonist and at least 2 hours before the next dose of the H2-receptor antagonist.

3. Antacids

The effect of antacids on the pharmacokinetics of erlotinib has not been evaluated. If antacid use is necessary, separate administration of antacids and erlotinib by several hours.